Cwm, LLC Acadia Pharmaceuticals Inc Transaction History

Cwm, LLC

$24.1 Billion
Q4 2024

A detailed history of Cwm, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Cwm, LLC holds 3,894 shares of ACAD stock, worth $57,864. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,894

Previous 2,248 73.22%

Holding current value

$57,864

Previous $35,000 102.86%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 04, 2025	BUY	$14.29 - $18.76 $23,521 - $30,878	1,646 Added 73.22%	3,894 $71,000
Q3 2024 Oct 08, 2024	BUY	$15.14 - $19.14 $2,059 - $2,603	136 Added 6.44%	2,248 $35,000
Q2 2024 Jul 09, 2024	BUY	$14.62 - $18.42 $1,403 - $1,768	96 Added 4.76%	2,112 $34,000
Q1 2024 Apr 05, 2024	BUY	$17.79 - $30.86 $426 - $740	24 Added 1.2%	2,016 $37,000
Q4 2023 Feb 01, 2024	SELL	$20.78 - $31.77 $1,475 - $2,255	-71 Reduced 3.44%	1,992 $62,000
Q3 2023 Oct 11, 2023	SELL	$20.84 - $33.47 $3,000 - $4,819	-144 Reduced 6.52%	2,063 $43,000
Q2 2023 Aug 03, 2023	SELL	$17.8 - $25.65 $2,812 - $4,052	-158 Reduced 6.68%	2,207 $53,000
Q1 2023 Apr 28, 2023	BUY	$16.32 - $20.92 $38,107 - $48,848	2,335 Added 7783.33%	2,365 $45,000
Q4 2022 Feb 01, 2023	SELL	$14.2 - $18.63 $880 - $1,155	-62 Reduced 67.39%	30 $0
Q3 2022 Oct 27, 2022	SELL	$14.11 - $18.27 $84 - $109	-6 Reduced 6.12%	92 $2,000
Q2 2022 Jul 28, 2022	BUY	$13.01 - $27.22 $299 - $626	23 Added 30.67%	98 $1,000
Q1 2022 Apr 21, 2022	BUY	$20.94 - $27.5 $900 - $1,182	43 Added 134.38%	75 $2,000
Q4 2021 Jan 31, 2022	BUY	$16.79 - $27.09 $436 - $704	26 Added 433.33%	32 $1,000
Q1 2019 Apr 22, 2019	BUY	$16.17 - $27.38 $97 - $164	6 New	6 $0

Others Institutions Holding ACAD

# of Institutions

321

Shares Held

165M

Call Options Held

855K

Put Options Held

350K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.4B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account